Recent News

• 02.25.2025 - Kiniksa Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call
• 02.25.2025 - Kiniksa Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call
• 02.25.2025 - Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution
• 02.25.2025 - Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution
• 02.25.2025 - Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution
• 02.25.2025 - Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy
• 02.25.2025 - Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy
• 02.25.2025 - Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy
• 02.20.2025 - Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
• 02.20.2025 - Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Recent Filings

• 02.25.2025 - EX-99.1 EX-99.1
• 02.25.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.25.2025 - 8-K Current report
• 02.25.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.10.2025 - 144 Report of proposed sale of securities
• 01.15.2025 - 4 Statement of changes in beneficial ownership of securities